📊 FULC Key Takeaways
Is FULC a Good Investment? Thesis Analysis
Fulcrum Therapeutics is a pre-revenue biopharmaceutical company with severe cash burn and no commercial revenue, indicating it has not successfully brought any products to market. With annual operating losses of $84.8M and free cash flow of -$60.4M, the company is in a critical runway phase despite maintaining $197.5M in cash reserves. The complete absence of revenue combined with substantial operating losses demonstrates the company faces significant execution risk in bringing pipeline programs to commercialization.
Why Buy FULC? Key Strengths
- Strong cash position of $197.5M provides runway for R&D operations
- No long-term debt obligations reduces financial leverage risk
- Excellent liquidity position with 27.4x current ratio ensures near-term solvency
- Significant stockholders equity of $349M provides balance sheet cushion
FULC Investment Risks to Consider
- Zero revenue with $84.8M annual operating losses indicates no approved commercial products
- Negative free cash flow of $60.4M annually means cash reserves deplete rapidly
- Diluted EPS of -$1.18 with extreme YoY deterioration shows persistent losses
- Pre-revenue status means company has not demonstrated ability to commercialize any assets
- Current cash burn rate suggests approximately 3.3 years of runway before cash depletion
- ROE of -21.5% and ROA of -20.4% indicate significant shareholder value destruction
Key Metrics to Watch
- Time to next major clinical milestone or regulatory approval
- Monthly cash burn rate trends and updated runway estimates
- Pipeline program advancement and clinical trial progress updates
- Quarterly revenue generation from any approved products
FULC Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 27.40x current ratio provides a solid financial cushion.
FULC Profitability Ratios
FULC vs Healthcare Sector
How Fulcrum Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is FULC Overvalued or Undervalued?
Based on fundamental analysis, Fulcrum Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
FULC Balance Sheet & Liquidity
FULC 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Fulcrum Therapeutics, Inc.'s revenue has grown significantly by 317% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.16 indicates the company is currently unprofitable.
FULC Growth Metrics (YoY)
FULC Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | $6.8M | $0.11 |
| Q2 2025 | N/A | -$17.3M | $-0.28 |
| Q3 2024 | N/A | $6.8M | $0.11 |
| Q2 2024 | $880.0K | -$23.8M | $-0.38 |
| Q1 2024 | N/A | -$24.8M | $-0.41 |
| Q3 2023 | $759.0K | -$23.7M | $-0.39 |
| Q1 2023 | $295.0K | -$23.8M | $-0.38 |
| Q3 2022 | $1.2M | -$17.0M | $-0.51 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
FULC Capital Allocation
FULC SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Fulcrum Therapeutics, Inc. (CIK: 0001680581)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FULC
What is the AI rating for FULC?
Fulcrum Therapeutics, Inc. (FULC) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are FULC's key strengths?
Claude: Strong cash position of $197.5M provides runway for R&D operations. No long-term debt obligations reduces financial leverage risk.
What are the risks of investing in FULC?
Claude: Zero revenue with $84.8M annual operating losses indicates no approved commercial products. Negative free cash flow of $60.4M annually means cash reserves deplete rapidly.
What is FULC's revenue and growth?
Fulcrum Therapeutics, Inc. reported revenue of $0.0.
Does FULC pay dividends?
Fulcrum Therapeutics, Inc. does not currently pay dividends.
Where can I find FULC SEC filings?
Official SEC filings for Fulcrum Therapeutics, Inc. (CIK: 0001680581) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FULC's EPS?
Fulcrum Therapeutics, Inc. has a diluted EPS of $-1.18.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is FULC a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Fulcrum Therapeutics, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is FULC stock overvalued or undervalued?
Valuation metrics for FULC: ROE of -21.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy FULC stock in 2026?
Our dual AI analysis gives Fulcrum Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FULC's free cash flow?
Fulcrum Therapeutics, Inc.'s operating cash flow is $-60.1M, with capital expenditures of $314.0K.
How does FULC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -21.5% (avg: 15%), current ratio 27.40 (avg: 2).